Repligen Cp (RGEN)
$126.13 2.54 (1.97%)
16:43 EDT RGEN Stock Quote Delayed 30 Minutes
Previous Close $126.13
Market Cap 5.51B
PE Ratio 177.65
Volume (Avg. Vol.) 242,300
Day's Range 125.85 - 129.07
52-Week Range 72.32 - 143.93
Dividend & Yield N/A (N/A)
RGEN Stock Predictions, Articles, and Repligen Cp News
- From InvestorPlace
- From the Web
While many companies were unable to avoid the wrath of the coronavirus pandemic, these three companies stood out as big winners.
Much of the conversation about pharmaceutical stocks rests on the coronavirus, but these high-growth names have potential beyond the pandemic.
Smart beta ETFs typically rebalance every 90 days. The next big rebalance will come in the next few weeks and likely push healthcare stock Repligen (RGEN) higher.
When rumors start buzzing that the government may be about to intervene, then biotech stocks often get slammed...some fairly, and some not (as we’ll see).
Despite the trade dispute with China, these biotech stocks each earn top marks in Portfolio Grader for fundamentals, earnings and momentum.
This morning, I am recommending a bullish trade on Repligen Corporation (NASDAQ:RGEN), the bioprocessing company.
With an aging population, pharma stocks can be a very profitable investments. These 5 biotechs probably aren't.
This week, the overall grades of 37 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
The following stocks were moving the Manufacturing sector today.
This week, 21 Biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").
The Manufacturing sector saw plenty of trading activity today, including the following leaders and losers.
Healthcare stocks rose broadly on Wall Street on Thursday morning, with the sector seeing an overall increase of 0.3%.
Healthcare stocks rose broadly on Wall Street on Friday, with the sector seeing an overall increase of 0.6%.
Healthcare stocks remained flat on Monday morning on Wall Street.
Healthcare stocks fell on Wall Street on Thursday morning, down 0.3%.
Healthcare stocks finished flat today on Wall Street.
From Analyst Ratings
Match Group (MTCH – Research Report) received a Buy rating and a $110.00 price target from SunTrust Robinson analyst Youssef Squali on July 6. The company’s shares closed last Wednesday at $94.16. According to TipRanks.com, Squali is a top 25 analyst with an average return of 33.0% and a 75.8% success rate. Squali covers the
From The Motley Fool
From The Motley Fool
Navellier RatingsPowered by Portfolio Grader